Hello, this is Daily Stock, deeply analyzing the key trends of the Kosdaq market and the future value of promising companies.
Summary
- Major buying interest flooded in on news that negotiations for an additional technology export have entered the final coordination stage, driving the stock price up 11.56% at the close.
- The unidentified non-exclusive ALT-B4 technology export partner from 2019 was officially confirmed to be the French big pharma Sanofi, proving global platform value.
- Q1 2026 operating profit margin reached 54.9%, entering a phase of financial value realization as commercialization milestones for Keytruda SC begin in earnest.
Current Situation Summary
Alteogen (196170), the top market-cap stock on the Kosdaq, closed at 371,500 KRW, up 11.56% from the previous session, driven by news that the conclusion of an additional technology export negotiation is imminent.
At the 'BIO USA 2026' event held in San Diego, USA, Alteogen CEO Tae-yeon Jun personally confirmed that licensing-out negotiations with global pharmaceutical companies have reached the final stages, attracting strong capital inflows.
On that day, foreign and institutional investors led the stock price surge, net purchasing 34.0 billion KRW and 74.0 billion KRW respectively, with foreign investors focusing their buying on Alteogen as their top net-buy stock in the Kosdaq market.
Additionally, market confidence was boosted as it was revealed for the first time that the partner for the 2.1 trillion KRW non-exclusive technology transfer signed back in 2019 was the French multinational pharmaceutical company Sanofi.
[Image: /stdaily/uploads/202606/gen_6a3b8f10513a60.56670445.png]
Financial Analysis
Alteogen's Q1 2026 earnings recorded revenue of 71.6 billion KRW and an operating profit of 39.3 billion KRW, achieving an unrivaled operating profit margin of 54.9%.
This was driven by the consecutive recognition of Q1 revenue from a licensing-out deal worth approximately 420.0 billion KRW with GSK's subsidiary Tesaro early this year, and a tech export deal worth approximately 850.0 billion KRW with Biogen in March.
From Q2 onwards, the receipt of full-scale commercialization milestones for Keytruda SC (US brand name Keytruda Qlex), which has secured an insurance billing code in the US, is expected, making the scenario for expanding operating strength even more concrete.
According to Daishin Securities' estimates, Alteogen's annual revenue and operating profit for this year are projected to reach 454.0 billion KRW and 295.0 billion KRW, up 110.4% and 176.3% year-on-year, respectively, making it the inaugural year of qualitative growth.
| Classification (Year/Quarter) | Revenue | Operating Profit | Operating Margin | Key Features |
|---|---|---|---|---|
| **Q1 2026** | 71.6 billion KRW | 39.3 billion KRW | 54.9% | Reflecting new tech exports to GSK and Biogen |
| **FY2026 Outlook** | 454.0 billion KRW | 295.0 billion KRW | 65.0% | Launch of Keytruda SC and full-scale milestones |
[Image: /stdaily/uploads/202606/gen_6a3b8f1a908b26.91794042.png]
Valuation
The subcutaneous (SC) formulation conversion technology 'Hybrozyme (ALT-B4)' platform acts as a valuation premium factor because, unlike a single new drug pipeline, it can be repeatedly applied to multiple blockbuster therapies.
Market evaluation criteria are also evolving from simply focusing on the total technology transfer contract amount to 'actual milestone inflows' and 'running royalty conversion value' resulting from entering the commercialization stage.
Over the next 3 to 4 years starting from this year, the cumulative milestones expected to flow in from MSD (Merck) are estimated at approximately 1 billion USD.
If recognized sequentially, high-margin inflows of over 300 billion KRW annually are possible, establishing a value scenario where running royalties of approximately 2% continue to be secured until the patent expiration date in 2043.
Expert and Institutional Analysis
Securities analysts highlight that the irreplaceable nature and commercial reliability of Alteogen's SC formulation conversion platform have reached their peak, serving as a primary valuation point.
Daishin Securities initiated coverage with a target price of 500,000 KRW, based primarily on the European marketing approval of Keytruda SC and the high probability of licensing deals with additional multinational companies.
In particular, they explained that no external invalidation trials have been filed against Alteogen's own proprietary patents, and even litigation attempts by competitor Halozyme were dismissed in the US, blocking concerns over technical disputes.
Accordingly, the average target price of analysts is formed around 458,000 KRW, indicating that an additional upside scenario relative to the current stock price is still active.
Risk Factors
However, because more than 90% of the tech export contracts consist of conditional milestones, investors must accept the possibility that expected capital inflows could be delayed if partner pharmaceutical companies face clinical delays or regulatory rejections.
Depending on revisions to the counterparty's development strategy, retrieving milestones step-by-step (excluding upfront payments) can involve a long timeline and multiple variables.
Additionally, it is worth noting that the management has reevaluated the planned transfer listing to the Kospi (main board) from scratch, citing benefits from Kosdaq policy and passive index advantages.
This presents a short-term volatility factor where short-term capital inflows of passive funds that entered in anticipation of the transfer listing may be delayed or undergo correction.
Investment Perspective Summary
Unlike typical biotech stocks whose share prices fluctuate wildly due to single clinical results, Alteogen shows a structure that has settled into a long-term growth trajectory through a proven technology platform.
Diversified pipeline contracts with over six global top-tier companies, including Sanofi and AstraZeneca, serve as a solid buffer supporting downside rigidity.
Currently, the Kospi Fear & Greed Index is at 40.2 (Neutral), and the Nasdaq Fear & Greed Index is at 27.7 (Fear), indicating that macroeconomic volatility remains.
Therefore, rather than aggressive chasing, an investment perspective that widens the response range for each scenario by verifying the scale of actual milestones and the confirmation of new license agreements starting in Q2 is recommended.
[Image: /stdaily/uploads/202606/gen_6a3b8f27eb7433.09082715.png]
Investor Checkpoint Q&A
Q1. What was the direct momentum that drove Alteogen's stock price surge today?
A1. It was because CEO Tae-yeon Jun stated in an official interview at the Bio USA event in the US that multiple additional tech export deals in progress with multinational big pharma companies are in the final stages of coordination.
Q2. Who is the partner company whose name was revealed for the first time in seven years?
A2. The protagonist who signed the 2.1 trillion KRW non-exclusive license agreement back in 2019 was revealed to be the French multinational big pharma 'Sanofi.'
Q3. What is the strongest advantage of Alteogen's platform technology?
A3. 'Hybrozyme (ALT-B4)' converts intravenous (IV) therapies into subcutaneous (SC) injections that patients can easily administer, and the single technology can be repeatedly applied to numerous partner firms in various ways.
Q4. What is the outlook for future earnings and valuation?
A4. The annual operating profit for 2026 is projected to increase by 176.3% year-on-year to 295.0 billion KRW, and massive cumulative royalty revenues of around 2% can continue until 2043.
Q5. What is the primary risk that investors should guard against first?
A5. Since most of the total contract value is structured as milestones paid only upon clinical success, investors must be mindful of risks regarding development timeline delays by global partners or unexpected regulatory approval delays.